Abstract
In spite of controversy on the advantage of atypical antipsychotic drugs (AAPDs) to treat cognitive impairment in schizophrenia (CIS) , substantial subsets of patients benefit from these compounds. There is extensive evidence for the ability of AAPDs of various profiles, e.g. more potent affinity for serotonin (5-HT) receptor subtypes versus dopamine (DA)-D2 receptors and actions on multi-receptors, including mGluR2/3, to enhance cognition. Therefore, further
investigations are needed into the heterogeneity in response to AAPDs within patients, specific cognitive domains relevant to outcome, and the neurobiological basis for the efficacy of AAPDs in model animals. The objective of this symposium involving presentations from Italy, USA, and Japan was to provide the evidence for the development of additional therapeutics for CIS.
